证券日报网讯12月9日，精华制药（002349）在互动平台回答投资者提问时表示，公司中成药产品尚未 出口到欧洲美国等地。 ...

Core Viewpoint - Jinghua Pharmaceutical (002349) is currently in the process of optimizing the production process for its product Mabalosavir, and it has not yet reached the conditions necessary for commercial production and sales [1] Company Summary - The company is actively working on the process optimization of Mabalosavir [1] - As of now, the product is not ready for commercial production and sales [1]

Group 1 - The company stated that its subsidiary's product, Dioxide Five Ring, is primarily used for the synthesis of co-polymer formaldehyde, with a small portion utilized in lithium iron phosphate battery electrolyte [1] - The pricing of the product is determined based on market demand, and its production and sales volume remain stable [1]

Core Viewpoint - The company clarifies the applications and market positioning of its products, specifically the use of its Dioxolane electrolyte solvent in comparison to carbonate solvents produced by listed companies, addressing investor concerns about product demand and market recognition [2]. Group 1: Product Applications - The company's Dioxolane products are primarily used in the synthesis of co-polymer formaldehyde, with a small portion utilized in lithium iron phosphate battery electrolyte [2]. - The pricing of Dioxolane products is determined based on market demand, indicating a responsive pricing strategy [2]. Group 2: Market Performance - The production and sales volume of the Dioxolane products have remained stable, suggesting consistent demand in the market [2]. - Despite the positive outlook for carbonate solvent companies, the company faces challenges in gaining market recognition, raising questions about its sales performance [2].

每经AI快讯，有投资者在投资者互动平台提问：公司玛巴洛沙韦还在改进中，是不是意味着短期无法 投放市场？ 精华制药（002349.SZ）12月9日在投资者互动平台表示，公司玛巴洛沙韦产品工艺优化工作尚在推进 中，目前还未具备商业化生产销售的条件。 （文章来源：每日经济新闻） ...

Industry News - The China Insurance Industry Association issued a risk warning regarding the "Anwo Stock Insurance" business, stating that it is not an approved insurance product and that stock investment losses are not insurable. The platform's activities may involve illegal financial operations [6]. - Beijing's Internet Information Office and the Beijing Financial Regulatory Bureau launched a three-month campaign to address six types of online financial misconduct, focusing on misleading public information and illegal financial services [7]. - The Ministry of Industry and Information Technology and five other departments released a plan to enhance the adaptability of supply and demand for consumer goods, aiming for a significant optimization of the supply structure by 2027, with three trillion-level consumption sectors and ten hundred-billion-level consumption hotspots [7]. - The Ministry of Natural Resources announced breakthroughs in the efficient extraction of low-grade rare metals from coal, aluminum, copper, lead, and zinc ores, with significant improvements in recovery rates for various metals [7]. - The first hydrogen refueling station in China utilizing underground hydrogen storage technology has been operational for over 1500 days, supplying over 400 tons of hydrogen, marking a significant advancement in high-pressure underground hydrogen storage technology [8]. Company News - Dongwei Technology announced a significant increase in PCB plating equipment orders, driven by rapid growth in the PCB and memory sectors, with expected record-high order amounts this year [11]. - North University Pharmaceutical stated that related flu medications have not yet been produced or sold, and this will not impact the company's performance for a considerable time [12]. - *ST Dongtong disclosed that its annual reports from 2019 to 2022 contained false records and has received a notice of termination of listing [13]. - Debang Technology's largest shareholder, the National Big Fund, reduced its stake by 2% between September 11 and October 16, completing its reduction plan [13]. - Muxi Co., Ltd. plans to issue 40.1 million shares, with the initial strategic placement of 8.02 million shares, and the subscription date set for December 5, 2025 [15].

(本文来自第一财经) 精华制药在互动平台表示，公司布局有玛巴洛沙韦等产品，目前玛巴洛沙韦的工艺优化工作尚在推进 中。 ...

格隆汇11月26日丨精华制药(002349.SZ)在投资者互动平台表示，目前玛巴洛沙韦的工艺优化工作尚在 推进中。 ...

Core Viewpoint - The company emphasizes its commitment to fair information disclosure by providing shareholder numbers in regular reports and allowing investors to verify their holdings through written documentation [1] Group 1 - The company will disclose the number of shareholders at the time of regular report releases [1] - For other months, investors can request shareholder numbers by providing proof of their shareholdings [1] - The company will verify shareholder identities before providing the requested information [1]

Core Insights - Jinghua Pharmaceutical's stock increased by 0.25% on November 11, with a trading volume of 182 million yuan, indicating active market participation [1] - The company reported a financing buy of 12.04 million yuan and a financing repayment of 16.41 million yuan on the same day, resulting in a net financing outflow of 4.37 million yuan [1] - As of November 11, the total margin balance for Jinghua Pharmaceutical was 177 million yuan, representing 2.71% of its market capitalization [1] Financing and Margin Data - On November 11, the financing buy amounted to 12.04 million yuan, while the current financing balance stands at 177 million yuan, which is above the 70th percentile of the past year [1] - The short selling data shows no shares were sold or repaid on November 11, with a remaining short position of 2,000 shares and a short balance of 16,000 yuan, indicating a low level of short selling activity [1] Company Overview - Jinghua Pharmaceutical, established on January 3, 1994, and listed on February 3, 2010, is based in Nantong, Jiangsu Province [1] - The company's main business includes the research, production, and sales of traditional Chinese medicine preparations, chemical raw materials, and biopharmaceuticals [1] - The revenue composition is as follows: traditional Chinese medicine preparations (39.22%), chemical pharmaceutical intermediates (23.51%), chemical raw materials (20.79%), and Chinese medicinal materials (15.80%) [1] Financial Performance - For the period from January to September 2025, Jinghua Pharmaceutical achieved a revenue of 1.092 billion yuan, reflecting a year-on-year growth of 4.51% [2] - The net profit attributable to shareholders for the same period was 176 million yuan, showing a year-on-year increase of 7.39% [2] Shareholder and Dividend Information - Since its A-share listing, Jinghua Pharmaceutical has distributed a total of 533 million yuan in dividends, with 205 million yuan distributed over the past three years [3] - As of September 30, 2025, the number of shareholders decreased by 7.36% to 88,800, while the average number of circulating shares per person increased by 7.94% to 9,167 shares [2][3] - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited holds 6.8555 million shares, a decrease of 1.6727 million shares from the previous period [3]